Clinical Trials Browser

Completed × farletuzumab × Clear all

NCT02289950 2021-09-02

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Phase 2 Completed

332 enrolled 14 charts

Platinum-Sensitive Ovarian Cancer in First Relapse

NCT01218516 2020-08-20

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase 2 Completed

130 enrolled 11 charts

Adenocarcinoma of Lung

NCT01049061 2020-06-11

A Study of MORAb-003 in Patients With Solid Tumor

Phase 1 Completed

Neoplasms

NCT00318370 2015-09-09

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Phase 2 Completed

58 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01004380 2014-07-17

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00428766 2013-11-06

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial